Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

CELLMUNE 0,3 MG/G POMADA - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/CELLMUNE 0,3 MG/G POMADA

Approved

STANDARD

CELLMUNE 0,3 MG/G POMADA

Industrial Farmaceutica Cantabria S.A.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Dec 22, 2022
Approval ID: ba0383c5cf548fdd
Company: Industrial Farmaceutica Cantabria S.A.
Type: Standard

Approval Details

Approval Id: ba0383c5cf548fdd
Drug Cima Aemps Name: CELLMUNE 0,3 MG/G POMADA
Register Number: 88431
Holder Company Name: Industrial Farmaceutica Cantabria S.A.
Marketing Company Name: Industrial Farmaceutica Cantabria S.A.
Authorization Date: 2022-12-22
Dosage Form: POMADA
Dose: 0,3 mg/g
Route Of Administration: USO CUTÁNEO
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Industrial Farmaceutica Cantabria S.A.

Active Ingredients

TACROLIMUS MONOHIDRATO

0,30 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Dec 22, 2022

Approval ID

ba0383c5cf548fdd

Type

Standard

Back to CIMA-AEMPS Approvals